Tagrisso (osimertinib) is a prescription medication used to treat non-small cell lung cancer (NSCLC). It is specifically designed for patients who have genetic mutations called epidermal growth factor receptor (EGFR) T790M-positive. In this blog post, we will discuss everything you need to know about Tagrisso prescribing information.
Introduction:
Lung cancer is one of the most common types of cancer and a leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) is responsible for approximately 85% of all lung cancer cases. Tagrisso is a targeted therapy treatment for NSCLC. Let’s delve deeper into its prescribing information.
What is Tagrisso?
Tagrisso is a prescription medication that belongs to the class of drugs known as tyrosine kinase inhibitors (TKIs). It works by blocking specific proteins in the body that help cancer cells grow. Tagrisso is specifically used to treat adults with advanced or metastatic NSCLC that has a specific genetic mutation known as the EGFR T790M-positive mutation.
Dosage and Administration:
Tagrisso comes in tablet form, and its dosage depends on various factors such as a patient’s individualized patient factors and the presence of drug interactions. The recommended dose is 80mg once per day, taken with or without food. Patients should continue to take their medication until their doctor advises them to stop.
Side Effects:
As with any medication, Tagrisso has the potential for side effects. The most common side effects of Tagrisso include diarrhea, rash, dry skin, and fatigue. More severe side effects may include interstitial lung disease (ILD), QT prolongation, and cardiac dysfunction. Patients are advised to report any unusual symptoms to their healthcare provider immediately.
Drug Interactions:
Tagrisso has the potential to interact with other medications, so it’s essential to inform your healthcare provider of any medications, vitamins, or herbal supplements you are taking. Drugs that may interact with Tagrisso include strong CYP3A inhibitors (such as ketoconazole) and CYP3A inducers (such as rifampicin), among others.
Conclusion:
Tagrisso prescribing information is crucial in guiding the use of this medication in the treatment of NSCLC. Patients should consult their healthcare provider regarding the appropriate usage of this medication, the potential side effects, and what to do if they encounter any adverse symptoms. With proper usage and medical supervision, Tagrisso has the potential to improve patient outcomes and quality of life.
(Note: Do you have knowledge or insights to share? Unlock new opportunities and expand your reach by joining our authors team. Click Registration to join us and share your expertise with our readers.)
Speech tips:
Please note that any statements involving politics will not be approved.